



Synthesis of bergenin-related natural products by way of an intramolecular C-glycosylation reaction

Cyril Rousseau and Olivier R. Martin *

Institut de Chimie Organique et Analytique (I.C.O.A.), Faculté des Sciences, BP 6759, 45067 Orléans cedex 2, France

Received 21 October 1999; accepted 2 November 1999

Abstract

The peracetate of tri-*O*-methylnorbergenin **16** as well as the *cis*-fused epimer of **16**, which constitutes the core *C*-aryl glycosidic fragment of castacrenin B, were prepared by way of the IDCP-mediated intramolecular *C*-arylation of a pentenyl β -D-glucopyranoside carrying, at O-2, a 3,4,5-trimethoxybenzyl substituent. © 2000 Elsevier Science Ltd. All rights reserved.

Bergenin **1**¹ and its derivatives norbergenin **2**² and tri-*O*-methylnorbergenin **3**³ are gallotannin-related natural products having the unusual structure of internal *C*-aryl glycosides (Fig. 1).⁴ Bergenin and its congeners occur widely in a number of plants and have been found as ingredients in plant extracts used in Indian folk medicine to treat venereal diseases.³ Recently, the *cis*-fused epimer of norbergenin was found to occur as a fragment of an ellagitannin metabolite, namely castacrenin B, isolated from the Japanese chestnut tree.⁵ The structures of bergenin and of castacrenin B are inviting targets for a synthesis by way of an intramolecular *C*-glycosylation procedure. However, attempts to prepare bergenin by such a strategy have failed so far.⁶





Fig. 1.

* Corresponding author. E-mail: olivier.martin@univ-orleans.fr

Bergenin itself has been obtained in very low yield by the reaction of acetobromoglucose with methyl 4-*O*-methyl gallate,¹ and its dimethyl ether **3** by a multistep synthesis by way of a *C*-glucopyranosyl benzene derivative.⁷ In preliminary studies,⁸ we have established that the internal *C*-glycosylation of gluco- and mannopyranose derivatives carrying, at *O*-2, a 3,4,5-trimethoxybenzoyl substituent could not be achieved, in spite of promising results in the furanose series.⁹ As a consequence, we examined a synthetic approach to these natural products by way of a two-step strategy, namely internal *C*-arylation of 2-*O*-benzylated pyranosides, followed by oxidation of the benzylic position to form the lactone function.

While the intramolecular alkylation of the benzyl group took place readily in sugars carrying, at *O*-2, a 3-methoxybenzyl or a 3,5-dimethoxybenzyl substituent,^{8,9} the conditions of the reaction (SnCl_4 , $\text{BF}_3 \cdot \text{Et}_2\text{O}$, etc.) were not compatible with a 3,4,5-trimethoxybenzyl group as they promoted rapid de-*O*-benzylation of the substrate. A solution was found to this problem by using, as the anomeric activator, a pentenyl glycoside,¹⁰ a function that can be activated selectively using a soft Lewis acid. We report herein the first synthesis of tri-*O*-methylnorbergenin and of the core *C*-glycosidic structure of castacrenin B by way of an internal *C*-glycosylation reaction.

The required precursor, partially protected pentenyl β -D-glucopyranoside **8**, was prepared in 59% overall yield from tetra-*O*-acetyl- α -D-glucopyranosyl bromide **5** by the orthoester procedure^{11,12} (Scheme 1): *O*-pentenyl orthoester **6** was obtained from **5** under Lemieux–Morgan conditions,¹¹ the acetyl groups of **6** were replaced by benzyl groups, and the orthoester **7** was rearranged into the corresponding pentenyl β -glycoside **8** by treatment with trimethylsilyl triflate¹³ followed by de-*O*-acetylation at *O*-2. Benzylation of **8** with highly reactive 3,4,5-trimethoxybenzyl chloride (from 3,4,5-trimethoxybenzyl alcohol and SOCl_2) provided substrate **9** (80%).




Scheme 1. Reagents and conditions. (a) 4-Penten-1-ol (3 equiv.), $n\text{Bu}_4\text{NBr}$, collidine; 83%. (b) KOH , BnBr , THF , Δ ; 84%. (c) (i) TMSOTf (cat.), CH_2Cl_2 , 0°C , 2 h; (ii) MeONa , MeOH ; 84%. (d) ArCH_2Cl , NaH , DMF ; 80%

The treatment of **9** with iodonium dicollidine perchlorate (IDCP)¹⁴ promoted the desired internal *C*-arylation reaction in excellent yield and without premature cleavage of the benzyl group at *O*-2 (Scheme 2). The resulting product was exclusively the kinetically favored,¹⁵ *cis*-fused tricyclic system **10** (' α -linked'). It is also noteworthy that iodination of the activated aromatic ring did not compete with the internal alkylation.¹⁶ Selective removal of the benzyl groups of **10** was realized by brief catalytic hydrogenation and the resulting product was acetylated to afford **11**. The benzylic position of **11** could then be oxidized using catalytic ruthenium tetroxide¹⁷ to give compound **12** (39% yield), a protected form of the core *C*-aryl glycoside of castacrenin B.

The NMR data of **12**¹⁸ were found to be in excellent agreement with those reported for the corresponding derivative of castacrenin B.⁵ Deacetylation of **12** gave the tri-*O*-methyl analog, compound **13**.¹⁹

It is of interest to note that the $^3\text{J}_{\text{H,H}}$ coupling constants in the pyranose ring of both **11** and **12** are all small ($\text{J}_{1,2}=3\text{Hz}$, other $^3\text{J}_{\text{H,H}}=3.8\text{--}5\text{Hz}$) which indicate that the conformation with an inverted chair ($^1\text{C}_4$ -type, see **I** in Fig. 2) is much more favorable for these compounds than the alternate $^4\text{C}_1$ chair form in which the *C*-aryl substituent would be axial.

The synthesis of bergenin and congeners required an epimerization at the newly created benzylic position (*C*-1). This inversion of configuration was deemed possible on the basis of the expected greater



Scheme 2. Reagents and conditions. (a) IDCP (2 equiv.), CH_2Cl_2 , 3 h, rt; 83%. (b) (i) H_2 , Pd/C, MeOH; (ii) Ac_2O , pyridine; 98%. (c) RuCl_3 (cat.), NaIO_4 , $\text{CCl}_4/\text{MeCN}/\text{H}_2\text{O}$, 18 h; 39%. (d) MeONa, MeOH; quant.

stability of the *trans*-fused (β -linked) bicyclic system (**II**) with respect to the *cis*-fused (α -linked) structure (**I**, Fig. 2) and of the likely sensitivity of the endocyclic benzylic $\text{C}_1\text{--O}_5$ bond to Lewis acids.





Fig. 2.

The treatment of **10** with an oxophilic Lewis acid promoted indeed the desired epimerization, albeit in a yield not exceeding 50%. The best results were obtained using $\text{BF}_3 \cdot \text{Et}_2\text{O}$. The resulting product, **14** (Scheme 3), was deprotected by hydrogenolysis and reacylated to give **15**, and the remaining primary benzylic position oxidized under the same conditions as **11** to give lactone **16** (68%). The ^1H and ^{13}C NMR data of this product **16**²⁰ were found to match those reported for the triacetate of tri-*O*-methyl-norbergenine.^{3,7}



Scheme 3. Reagents and conditions. (a) $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (cat.), CH_2Cl_2 , 2 h, 0°C to rt; 48%. (b) (i) H_2 , Pd/C, MeOH; (ii) Ac_2O , pyridine; 95%. (c) RuCl_3 (cat.), NaIO_4 , $\text{CCl}_4/\text{MeCN}/\text{H}_2\text{O}$, 18 h; 68%

In conclusion, we have achieved the first synthesis of tri-*O*-methylnorbergenin triacetate, as well as of the core *C*-aryl glycoside of castacrenin B by way of an intramolecular *C*-glycosylation. This work demonstrates that pentenyl glycosides constitute very convenient substrates for the internal alkylation/glycosylation of highly Lewis-acid sensitive benzyl groups.

References

- Hay, J. E.; Haynes, L. J. *J. Chem. Soc.* **1958**, 2231.
- Taneyama, M.; Yoshida, S.; Kobayashi, M.; Hasegawa, M. *Phytochemistry* **1983**, 1053.
- Ramaiah, P. A.; Row, L. R.; Reddy, D. S.; Anjaneyulu, A. S. R.; Ward, R. S.; Pelter, A. *J. Chem. Soc., Perkin Trans. 1* **1979**, 2313.

4. Frick, W.; Hofmann, J.; Fischer, H.; Schmidt, R. R. *Carbohydr. Res.* **1991**, *210*, 71.
5. Tanaka, T.; Ueda, N.; Shinohara, H.; Nonaka, G.-I.; Fujioka, T.; Mihashi, K.; Kouno, I. *Chem. Pharm. Bull.* **1996**, *44*, 2236.
6. Schmidt, R. R.; Effenberger, G. *Carbohydr. Res.* **1987**, *171*, 59. However, the structure of compounds **23** and **24** in that reference were later shown to be in error: see Ref. 4.
7. Frick, W.; Schmidt, R. R. *Carbohydr. Res.* **1991**, *209*, 101.
8. Martin, O. R.; Deshpande, P. P., unpublished results.
9. Martin, O. R.; Hendricks, C. A. V.; Deshpande, P. P.; Cutler, A. B.; Kane, S. A.; Rao, S. P. *Carbohydr. Res.* **1990**, *196*, 41.
10. Fraser-Reid, B.; Udodong, U. E.; Wu, Z.; Ottoson, H.; Merritt, J. R.; Rao, C. S.; Roberts, C.; Madsen, R. *Synlett* **1992**, 927.
11. Lemieux, R. U.; Morgan, A. R. *Can. J. Chem.* **1965**, *43*, 2199.
12. For other examples of *O*-pentenyl orthoesters, see: (a) Roberts, C.; Madsen, R.; Fraser-Reid, B. *J. Am. Chem. Soc.* **1995**, *117*, 1546. (b) Allen, J. G.; Fraser-Reid, B. *J. Am. Chem. Soc.* **1999**, *121*, 468.
13. (a) Ogawa, T.; Beppu, K.; Nakabayashi, S. *Carbohydr. Res.* **1981**, *93*, C6. (b) Gass, J.; Strobl, M.; Loibner, A.; Kosma, P.; Zaehring, U. *Carbohydr. Res.* **1993**, *244*, 69.
14. Winstein, S.; Buckles, R. E. *J. Am. Chem. Soc.* **1942**, *64*, 2780. For its use in *O*-glycosylation reactions, see Ref. 10.
15. The internal *C*-arylation of a 2-*O*-benzyl glucopyranosyl chloride gave exclusively the α -linked (*cis*-fused) product: Verlhac, P.; Leteux, C.; Toupet, L.; Veyrières, A. *Carbohydr. Res.* **1996**, *291*, 11.
16. Partial iodination of the ring occurred in the course of the internal *C*-arylation of the 2-*O*-(3,5-dimethoxybenzyl) derivative of **8** using IDCP.
17. Carlsen, P. J. H.; Katsuki, T.; Martin, V. S.; Sharpless, K. B. *J. Org. Chem.* **1981**, *46*, 3936.
18. M.p.: 141–142°C; $[\alpha]_D^{20} +20.8$ ($c=1.5$, CHCl₃); ¹H NMR (250 MHz, CDCl₃): δ 2.08 (s, 6H), 2.12 (s, 3H) (3OAc), 3.89, 3.91, 3.93 (3s, 9H, 3OMe), 4.12 (m, 1H, $J_{4,5}=3.8$ Hz, H-5), 4.32 (dd, 1H, $J_{5,6a}=4.7$, $J_{6a,6b}=12.0$ Hz, H-6a), 4.45 (br t, 1H, $J=3.3$ Hz, H-2), 4.53 (dd, 1H, $J_{5,6b}=7.2$ Hz, H-6b), 4.94 (t, 1H, $J=4.1$ Hz, H-4 or 3), 5.19 (d, 1H, $J_{1,2}=3.0$ Hz, H-1), 5.31 (t, 1H, $J=4$ Hz, H-3 or 4), 7.45 (s, 1H, H_{ar}); ¹³C NMR (62.9 MHz): δ 20.75 (3C), 56.28, 60.84 (C-6), 61.02, 61.91, 65.85, 68.09, 73.11, 73.54, 108.81 (ArCH), 119.97, 122.89, 147.46, 150.76, 154.8, 162.5, 168.75, 169.9, 170.53.
19. ¹³C NMR (62.9 MHz, CD₃OD): δ 57.2, 61.43, 61.98, 62.54, 63.12, 69.58, 73.51, 80.87, 81.62, 109.94, 121.82, 126.07, 149.41, 152.93, 156.49, 166.01.
20. $[\alpha]_D -8.7 \pm 0.8$ ($c=1.3$, CHCl₃) {lit.⁷ $[\alpha]_D -8$ ($c=1$, CHCl₃)}; ¹H NMR (250 MHz, CDCl₃): δ 2.05, 2.08, 2.09 (3s, 3×3H, 3OAc), 3.84, 3.89, 3.93 (3s, 3×3H, 3OMe), ~3.85 (occluded m, 1H, H-5), 4.24–4.35 (m, 2H, H-6a,6b), 4.28 (t, 1H, $J=10$ Hz, H-2), 4.81 (d, 1H, $J_{1,2}=10.3$ Hz, H-1), 5.10 (t, 1H, $J=9.6$ Hz, H-4 or 3), 5.50 (t, 1H, $J=9.4$ Hz, H-3 or 4), 7.43 (s, 1H, H_{ar}); ¹³C NMR (62.9 MHz): δ 20.63, 20.74, 20.82, 56.28, 61.08, 61.71, 62.46, 68.87, 72.31, 72.50, 77.20, 109.92, 118.8, 124.95, 148.92, 151.3, 154.05, 163.0, 169.75, 170.16, 170.59; one carbon hidden by the ¹³CDCl₃ signal.